Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

Affiliation auteurs!!!! Error affiliation !!!!
TitreBaseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
Type de publicationJournal Article
Year of Publication2020
AuteursNiogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc F-X, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux J-L, Etienne P-L, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F
JournalCANCERS
Volume12
Pagination1429
Date PublishedJUN
Type of ArticleArticle
Mots-cléscirculating monocytic myeloid derived suppressor cells, MDSC, metastatic colorectal cancer, Prognostic biomarker, splenomegaly
Résumé

{Background: Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan. Methods: This study is a sub-study of PRODIGE-9 study, which included 488 mCRC patients treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab in first line. The association between splenic volume, and PFS and OS was evaluated by univariate and multivariable Cox analyses. The relation between circulating monocytic Myeloid derived suppressor cells (mMDSC) and splenomegaly was also determined. Results: Baseline splenic volume > 180 mL was associated with poor PFS (median PFS = 9.2 versus 11.1 months; log-rankp= 0.0125), but was not statistically associated with OS (median OS = 22.6 versus 28.5 months; log-rankp= 0.1643). The increase in splenic volume at 3 months had no impact on PFS (HR 0.928; log-rankp= 0.56) or on OS (HR 0.843; log-rankp= 0.21). Baseline splenic volume was positively correlated with the level of baseline circulating mMDSC (r= 0.48
DOI10.3390/cancers12061429